Livzon Pharmaceutical Gro... (LVZPF)
Livzon Pharmaceutical Statistics
Share Statistics
Livzon Pharmaceutical has 1.17B shares outstanding. The number of shares has increased by -8.89% in one year.
| Shares Outstanding | 1.17B |
| Shares Change (YoY) | -8.89% |
| Shares Change (QoQ) | -3.3% |
| Owned by Institutions (%) | n/a |
| Shares Floating | n/a |
| Failed to Deliver (FTD) Shares | n/a |
| FTD / Avg. Volume | n/a |
Short Selling Information
| Short Interest | n/a |
| Short % of Shares Out | n/a |
| Short % of Float | n/a |
| Short Ratio (days to cover) | n/a |
Valuation Ratios
The PE ratio is 11.18 and the forward PE ratio is null. Livzon Pharmaceutical's PEG ratio is 1.68.
| PE Ratio | 11.18 |
| Forward PE | n/a |
| PS Ratio | 1.95 |
| Forward PS | n/a |
| PB Ratio | 1.66 |
| P/FCF Ratio | 9.56 |
| PEG Ratio | 1.68 |
Enterprise Valuation
Livzon Pharmaceutical has an Enterprise Value (EV) of 16.14B.
| EV / Sales | 1.37 |
| EV / EBITDA | 4.65 |
| EV / EBIT | 5.42 |
| EV / FCF | 6.7 |
Financial Position
The company has a current ratio of 2.15, with a Debt / Equity ratio of 0.28.
| Current Ratio | 2.15 |
| Quick Ratio | 1.89 |
| Debt / Equity | 0.28 |
| Debt / EBITDA | 1.13 |
| Debt / FCF | 1.63 |
| Interest Coverage | 32.1 |
Financial Efficiency
Return on Equity is 14.87% and Return on Invested Capital is 12.11%.
| Return on Equity | 14.87% |
| Return on Assets | 8.43% |
| Return on Invested Capital | 12.11% |
| Revenue Per Employee | $1,302,783.59 |
| Profits Per Employee | $227,318.39 |
| Employee Count | 9,067 |
| Asset Turnover | 0.48 |
| Inventory Turnover | 2.04 |
Taxes
| Income Tax | 501.66M |
| Effective Tax Rate | 17.88% |
Stock Price Statistics
The stock price has increased by 7.19% in the last 52 weeks. The beta is 0.41, so Livzon Pharmaceutical's price volatility has been higher than the market average.
| Beta | 0.41 |
| 52-Week Price Change | 7.19% |
| 50-Day Moving Average | 3.43 |
| 200-Day Moving Average | 3.37 |
| Relative Strength Index (RSI) | 46.38 |
| Average Volume (20 Days) | 81 |
Income Statement
In the last 12 months, Livzon Pharmaceutical had revenue of 11.81B and earned 2.06B in profits. Earnings per share was 2.24.
| Revenue | 11.81B |
| Gross Profit | 7.73B |
| Operating Income | 2.84B |
| Net Income | 2.06B |
| EBITDA | 3.47B |
| EBIT | 2.89B |
| Earnings Per Share (EPS) | 2.24 |
Balance Sheet
The company has 10.83B in cash and 3.93B in debt, giving a net cash position of 6.89B.
| Cash & Cash Equivalents | 10.83B |
| Total Debt | 3.93B |
| Net Cash | 6.89B |
| Retained Earnings | 11.76B |
| Total Assets | 24.49B |
| Working Capital | 9.23B |
Cash Flow
In the last 12 months, operating cash flow was 2.98B and capital expenditures -570.16M, giving a free cash flow of 2.41B.
| Operating Cash Flow | 2.98B |
| Capital Expenditures | -570.16M |
| Free Cash Flow | 2.41B |
| FCF Per Share | 2.62 |
Margins
Gross margin is 65.45%, with operating and profit margins of 24.08% and 17.45%.
| Gross Margin | 65.45% |
| Operating Margin | 24.08% |
| Pretax Margin | 23.76% |
| Profit Margin | 17.45% |
| EBITDA Margin | 29.38% |
| EBIT Margin | 24.08% |
| FCF Margin | 20.39% |
Dividends & Yields
LVZPF pays an annual dividend of $0.34, which amounts to a dividend yield of 4.39%.
| Dividend Per Share | $0.34 |
| Dividend Yield | 4.39% |
| Dividend Growth (YoY) | -19.1% |
| Payout Ratio | 112.29% |
| Earnings Yield | 8.95% |
| FCF Yield | 10.46% |
Analyst Forecast
Currently there are no analyst rating for LVZPF.
| Price Target | n/a |
| Price Target Difference | n/a |
| Analyst Consensus | n/a |
| Analyst Count | n/a |
Stock Splits
The last stock split was on Dec 23, 2019. It was a forward split with a ratio of 13:10.
| Last Split Date | Dec 23, 2019 |
| Split Type | forward |
| Split Ratio | 13:10 |
Scores
| Altman Z-Score | 2.3 |
| Piotroski F-Score | 6 |